Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
18F-Fluciclatide PET/CT in Multiple Myeloma and Precursors
NCT01571726Phase 2Withdrawn
- Sponsor
- National Cancer Institute
- Start
- Mar 2012
- Primary completion
- Apr 2014
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of fluciclatide in multiple myeloma (MM), smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS), sponsored by National Cancer Institute. Primary endpoint: Distribution of 18F-Fluciclatide PET/CT in bone marrow microenvironment at 1 year. Planned start Mar 2012; status: withdrawn.
02
Drugs
fluciclatide
03
Conditions
multiple myeloma (MM)smoldering multiple myeloma (SMM)monoclonal gammopathy of undetermined significance (MGUS)
Beyond the preview
Go deeper on NCT01571726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01571726.